CMP 001

Drug Profile

CMP 001

Alternative Names: ARB 1598; CMP-001; CYT 003 QbetaG10; CYT-003; CYT003 PolQb; CYT003 PolQbeta; CYT003-QbG10; Immunodrug™ CYT003-QbG10; QbG10; Virus-like particle-based cancer vaccine - Checkmate; VLP-based cancer vaccine - Checkmate

Latest Information Update: 09 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cytos Biotechnology
  • Developer Arbutus Biopharma; Checkmate Pharmaceuticals; Cytos Biotechnology; Genocea Biosciences
  • Class Allergy immunotherapies; Antiallergics; Cancer vaccines; Oligonucleotides; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants; Toll-like receptor 9 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Malignant melanoma
  • Preclinical Lymphoma
  • Discontinued Allergic asthma; Atopic dermatitis; Hepatitis B; Perennial allergic rhinitis; Seasonal allergic rhinitis

Most Recent Events

  • 01 Apr 2017 Pharmacodynamics data from preclinical studies presented at the 108th Annual Meeting of the American Association for Cancer Research
  • 23 Mar 2017 Checkmate Pharmaceuticals plans a phase I/II trial for Malignant melanoma (Combination therapy, Second-line therapy or greater, Metastatic disease, Late-stage disease) (NCT03084640)
  • 09 Feb 2017 Checkmate Pharmaceuticals plans a phase I trial for lymphoma in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top